IDO1 and central nervous system cancer: Gliomas, for instance, scarcely express IDO17,28 and IDO1 does not account for the constitutive Trp degradation observed in these tumours.7 Therefore, efficacy of IDO1 inhibition by EOS-200271, for example, might not be expected in malignant gliomas.